<DOC>
	<DOCNO>NCT00003020</DOCNO>
	<brief_summary>RATIONALE : LMB-7 immunotoxin locate tumor cell kill without harm normal cell . PURPOSE : Phase I trial study effectiveness LMB-7 immunotoxin treat patient leptomeningeal metastasis metastasis .</brief_summary>
	<brief_title>LMB-7 Immunotoxin Treating Patients With Leptomeningeal Metastases</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity intrathecal LMB-7 immunotoxin patient leptomeningeal metastasis . II . Identify objective therapeutic response group patient . OUTLINE : This dose escalation study . Patients receive LMB-7 intrathecally day 1 , 3 , 5 . Treatment may repeat every 4 week patient demonstrate HAMA neutralize antibody PE-38 CSF , stable respond disease , experience great grade II toxicity . Three six patient enter dose level . Dose escalation continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience grade 3 bad toxicity neuroradiology toxicity score 10 great . PROJECTED ACCRUAL : Approximately 15 24 patient accrue one year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary intracranial extraneural neoplasm leptomeningeal metastasis At least 30 % malignant cell cerebrospinal fluid , primary tumor , metastatic tumor must react B3 mouse monoclonal antibody PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : ANC great 1000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.2 mg/dL Pulmonary : DLCO least 60 Other : No neutralize antibody Pseudomonas exotoxin Not pregnant nursing Not allergic penicillin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No chemotherapy within past 4 week ( 6 week nitrosoureas ) unless evidence disease progression CNS No concurrent chemotherapy Endocrine therapy : Patients receive corticosteroid must stable dose 10 day prior entry Radiotherapy : No radiotherapy disease site within past 3 month unless evidence disease progression CNS No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>leptomeningeal metastasis</keyword>
</DOC>